Thermo Fisher Scientific Inc.
TMO
$574.30
-0.43%
Thermo Fisher Scientific is a global leader in serving science, providing scientific instruments, laboratory equipment, diagnostics consumables, and life science reagents to research, healthcare, and industrial customers. As the dominant player in the life sciences tools and diagnostics industry, it operates through four segments: analytical technologies, specialty diagnostics, life science solutions, and lab products/services including CRO. The current investor narrative centers on the company's ability to sustain mid-single-digit revenue growth amid geopolitical tensions and modest inflation risks, while leveraging its scale to expand margins and generate robust free cash flow.…
TMO
Thermo Fisher Scientific Inc.
$574.30
Investment Opinion: Should I buy TMO Today?
Rating: Hold. Thesis: Thermo Fisher is a high-quality business with durable competitive advantages, but the current valuation offers limited upside relative to risks. The analyst consensus is Buy with an average target of $615.12 (8.2% upside), but the stock's premium valuation and macro uncertainties warrant a cautious stance.
Supporting Evidence: The forward P/E of 20.8x is attractive relative to its own history (5-year range 24x-43x) but above the sector median. Revenue grew 6.2% YoY in Q1 2026, and operating margins improved to 16.9%. Free cash flow of $6.75B TTM supports a dividend yield of 0.29% and reinvestment. The implied upside to the average analyst target is 8.2%, which is modest. The stock's PEG ratio of 4.54 suggests the market is pricing in high growth expectations.
Risks & Conditions: The Hold rating could upgrade to Buy if the stock pulls back to $510 (analyst low target) or if forward P/E compresses below 18x, offering a wider margin of safety. Conversely, a downgrade to Sell would be warranted if revenue growth decelerates below 4% or if margins contract further. The stock appears fairly valued relative to its history but overvalued relative to peers. Investors should wait for a better entry point or a clearer catalyst.
Sign up to view all
TMO 12-Month Price Forecast
Thermo Fisher's outlook is balanced. The base case of mid-single-digit growth and stable margins is most probable, supporting a price near the analyst average. However, the stock's premium valuation leaves little room for error. A neutral stance is warranted given the modest upside and macro risks. Upgrades would require evidence of accelerating growth or a pullback to a more attractive valuation. Downgrades would follow margin compression or a growth miss.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Thermo Fisher Scientific Inc.'s 12-month outlook, with a consensus price target around $627.62 and implied upside of +9.3% versus the current price.
Average Target
$627.62
0 analysts
Implied Upside
+9.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$520 - $750
Analyst target range
The stock is covered by 26 analysts, with a consensus recommendation of 'Buy' (mean score 1.61 on a 1-5 scale). The average target price is $615.12, implying 8.2% upside from the current price of $568.26. The distribution leans bullish, with no sell ratings in the recent institutional actions (e.g., Evercore, Barclays, Citigroup all maintain positive ratings). The target range spans from $510.00 (low) to $750.00 (high). The high target of $750 assumes 32% upside, likely factoring in margin expansion and accelerated growth from new product cycles. The low target of $510 implies a 10% downside, pricing in potential margin compression or slower growth. The wide spread ($240) indicates high uncertainty, but the recent upgrades (e.g., HSBC downgraded to Hold, but others maintained Buy) suggest mixed sentiment. Overall, the consensus is moderately bullish with conviction in the company's long-term prospects.
Drowning in data?
Find the real signal!
Bulls vs Bears: TMO Investment Factors
Thermo Fisher presents a balanced risk/reward profile. The bull case rests on its dominant market position, strong cash flow, and attractive forward valuation relative to history. The bear case highlights premium valuation vs. peers, decelerating growth, and macro risks. The single most important tension is whether the company can deliver the earnings growth implied by the forward P/E (20.8x) amid modest inflation and geopolitical headwinds. Currently, the evidence slightly favors the bulls given the analyst consensus and improving margins, but the stock's recent volatility warrants caution.
Bullish
- Dominant Market Position: Thermo Fisher is the global leader in life sciences tools and diagnostics, with a diversified revenue base across four segments. This scale provides pricing power and resilience, as evidenced by 6.2% YoY revenue growth in Q1 2026 to $11.0 billion.
- Strong Free Cash Flow Generation: TTM free cash flow stands at $6.75 billion, providing ample capacity for debt reduction, dividends ($162M quarterly), and strategic M&A. This financial flexibility supports long-term value creation.
- Attractive Forward Valuation: The forward P/E of 20.8x is well below the trailing P/E of 32.6x, implying significant expected earnings growth. This gap suggests the market is pricing in a recovery, and the stock trades near the lower end of its 5-year P/E range (24x-43x).
- Analyst Consensus Buy with Upside: 26 analysts rate the stock a Buy (mean 1.61/5), with an average target of $615.12, implying 8.2% upside. The high target of $750 suggests 32% potential upside if growth accelerates.
Bearish
- Premium Valuation vs. Peers: The trailing P/E of 32.6x is above the sector median (estimated ~25x), reflecting a premium for its market leadership. If growth disappoints, multiple compression could pressure the stock.
- Revenue Growth Deceleration: Revenue growth has slowed from pandemic-driven highs to mid-single digits (6.2% YoY). The instruments segment ($1.6B) lags, and any further deceleration could undermine the growth narrative.
- Geopolitical and Inflation Risks: Management flagged 'modest inflation' risk from Middle East tensions, which could pressure margins. Additionally, global trade disruptions may impact supply chains and customer spending.
- High Earnings Expectations: The forward P/E of 20.8x implies robust earnings growth, but consensus EPS estimates of $38.14 for FY2026 require sustained margin expansion. Any miss could trigger a sharp re-rating.
TMO Technical Analysis
The stock is in a recovery uptrend after a sharp decline, with a 1-year price change of +19.6% and currently trading at $568.26, which is 88% of its 52-week range ($435.27-$643.99). This positioning near the upper end of the range suggests bullish momentum but also potential overextension after a strong rebound from the lows. The 1-month price change of +15.5% and 3-month change of +21.0% indicate accelerating short-term momentum, diverging from the 6-month decline of -9.2%. This divergence signals a potential trend reversal from the earlier downtrend, supported by a relative strength of +14.7% vs. SPY over 1 month. The 52-week low of $435.27 provides key support, while resistance at the 52-week high of $643.99 represents a 13% upside. A breakout above $644 would signal a resumption of the long-term uptrend, while a breakdown below $435 could indicate further weakness. Beta is not provided, but the stock's volatility is evident from the 31.5% max drawdown over the period.
Beta
0.87
0.87x market volatility
Max Drawdown
-31.4%
Largest decline past year
52-Week Range
$435-$644
Price range past year
Annual Return
+22.8%
Cumulative gain past year
| Period | TMO Return | S&P 500 |
|---|---|---|
| 1m | +11.9% | +0.2% |
| 3m | +22.4% | +3.7% |
| 6m | -0.7% | +8.0% |
| 1y | +22.8% | +18.2% |
| ytd | -3.1% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMO Fundamental Analysis
Revenue grew 6.2% year-over-year in Q1 2026 to $11.0 billion, with sequential improvement from Q4 2025's $12.2 billion. The multi-quarter trend shows deceleration from 2021's pandemic-driven highs but stable mid-single-digit growth, driven by consumables ($4.7B) and service ($4.7B) segments, while instruments ($1.6B) lag. Net income was $1.65 billion in Q1 2026, with gross margin of 40.7% and operating margin of 16.9%. Margins have compressed from 2021 levels (gross margin 46.1%) but stabilized recently, with Q1 2026 operating margin improving from Q2 2025's 17.7%. The company is solidly profitable with a net margin of 15.0%. Free cash flow was $816 million in Q1 2026, with TTM FCF of $6.75 billion. Debt-to-equity is 0.76, and the current ratio of 1.89 indicates healthy liquidity. ROE of 12.6% reflects efficient capital use, and the company generates sufficient cash to fund operations and dividends ($162M quarterly) while maintaining investment capacity.
Quarterly Revenue
$11.0B
2026-03
Revenue YoY Growth
+6.2%
YoY Comparison
Gross Margin
40.7%
Latest Quarter
Free Cash Flow
$6.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMO Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 32.6x, while the forward P/E is 20.8x, implying the market expects significant earnings growth. The gap between trailing and forward P/E suggests strong growth expectations embedded in the current price. Compared to the industry (Medical - Diagnostics & Research), the stock trades at a premium: the trailing P/E of 32.6x is above the sector median (not provided, but typically ~25x), reflecting its market leadership and stable growth. Historically, the trailing P/E of 32.6x is near the lower end of its 5-year range (which peaked at ~43x in early 2022 and bottomed at ~24x in mid-2023). This suggests the stock is not excessively valued relative to its own history, offering a potential entry point if growth materializes.
PE
32.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 24x~43x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Thermo Fisher carries a debt-to-equity ratio of 0.76, which is manageable but not negligible. Interest expense of $354 million in Q1 2026 consumes a portion of operating income ($1.86B). The company's net margin of 15.0% is solid, but gross margin compression from 46.1% in 2021 to 40.7% in Q1 2026 highlights post-pandemic normalization. Free cash flow of $6.75B TTM provides a cushion, but any sustained margin pressure could reduce investment capacity. Revenue concentration in consumables and services (combined ~85% of sales) is a strength, but the instruments segment's sluggishness (17% of sales) could weigh on overall growth.
Market & Competitive Risks: The stock's trailing P/E of 32.6x is a premium to the sector median, making it vulnerable to valuation compression if growth disappoints. The stock's beta is not provided, but its 31.5% max drawdown indicates high sensitivity to market downturns. Competitive threats from Danaher, Agilent, and emerging players could pressure market share. Regulatory risks include changes in healthcare funding or laboratory budgets. The recent news of 'modest inflation' risk from Middle East tensions adds a macro overlay that could dampen demand.
Worst-Case Scenario: A confluence of sustained inflation, geopolitical escalation, and a sharp slowdown in research spending could cause revenue growth to stall below 3%. In this scenario, the forward P/E could contract to 18x (near the low end of its historical range), implying a price of ~$510 (the analyst low target). From the current $568.26, this represents a 10% downside. However, a more severe recession could push the stock to the 52-week low of $435.27, a 23% decline. The realistic worst-case loss is approximately -23% to $435.27.
FAQ
The key risks are: 1) Valuation risk: The trailing P/E of 32.6x is a premium to peers, leaving the stock vulnerable to multiple compression if growth disappoints. 2) Growth deceleration: Revenue growth has slowed to 6.2% YoY, and any further slowdown could undermine the investment thesis. 3) Macro risks: Management flagged 'modest inflation' from Middle East tensions, which could pressure margins and demand. 4) Competitive risk: Danaher, Agilent, and others compete in key segments, potentially pressuring market share. The most severe risk is a combination of slowing growth and margin compression, which could drive the stock to the 52-week low of $435.27, a 23% downside from current levels.
The 12-month forecast is balanced among three scenarios. The base case (50% probability) sees the stock trading near the analyst average target of $615, driven by mid-single-digit revenue growth and stable margins. The bull case (25% probability) targets $615-$750, assuming accelerated growth and margin expansion. The bear case (25% probability) sees the stock falling to $435-$510, if growth slows and margins compress. The most likely scenario is the base case, with the stock offering modest upside. Key assumptions include sustained consumables demand and stable operating margins around 17%.
TMO's trailing P/E of 32.6x is above the sector median (estimated ~25x), suggesting a premium for its market leadership. However, the forward P/E of 20.8x is below its 5-year average of ~30x, indicating the market expects significant earnings growth. Compared to its own history, the stock is fairly valued near the lower end of its 5-year P/E range (24x-43x). The PEG ratio of 4.54 implies the market is pricing in high growth expectations. Overall, TMO appears fairly valued relative to its history but overvalued relative to peers. The valuation implies the market expects mid-single-digit revenue growth and margin expansion to continue.
Thermo Fisher is a high-quality business with a durable competitive advantage, but the current price offers limited upside. The analyst consensus is Buy with an average target of $615.12, implying 8.2% upside. However, the trailing P/E of 32.6x is above the sector median, and the stock is only 11.8% below its 52-week high. The biggest downside risk is a growth deceleration that could compress the multiple. For long-term investors with a 3-5 year horizon, TMO is a solid hold, but for those seeking near-term gains, a better entry point may emerge on pullbacks. It is a good buy for patient investors willing to accept modest near-term returns.
TMO is best suited for long-term investment. The company's dominant market position, strong free cash flow ($6.75B TTM), and diversified revenue base make it a reliable compounder. The stock's beta is not provided, but its 31.5% max drawdown indicates moderate volatility, which may be uncomfortable for short-term traders. The dividend yield is low (0.29%), so income-focused investors may look elsewhere. A minimum holding period of 3-5 years is recommended to allow the growth story to play out. Short-term trading is possible given recent momentum (+15.5% in 1 month), but the modest upside to the analyst target suggests limited near-term gains.
